M.D.C. (NYSE:MDC) Lowered to “Sell” at ValuEngine
MDC has been the subject of several other reports. Wedbush increased their price objective on shares of M.D.C. from $35.00 to $41.00 and gave the stock a neutral rating in a research report on Friday, September 13th. Zelman & Associates downgraded M.D.C. from a buy rating to a hold rating in a report on Thursday, October 31st. Raymond James upgraded M.D.C. from an outperform rating to a strong-buy rating and increased their price target for the stock from $42.00 to $49.00 in a report on Friday, September 13th. Cfra raised M.D.C. from a hold rating to a buy rating in a research report on Thursday, October 31st. Finally, Zacks Investment Research downgraded M.D.C. from a buy rating to a hold rating in a research note on Tuesday, November 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $44.00.
Shares of M.D.C. stock traded up $0.21 during midday trading on Tuesday, reaching $39.35. The company had a trading volume of 1,292 shares, compared to its average volume of 552,521. The stock has a fifty day moving average price of $40.89 and a 200 day moving average price of $37.76. M.D.C. has a fifty-two week low of $25.77 and a fifty-two week high of $46.84. The firm has a market cap of $2.43 billion, a PE ratio of 10.69, a P/E/G ratio of 1.09 and a beta of 1.03. The company has a debt-to-equity ratio of 0.66, a current ratio of 9.08 and a quick ratio of 1.83.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.05%. The ex-dividend date was Tuesday, November 12th. M.D.C.’s payout ratio is 32.70%.
In related news, Director Michael A. Berman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $70.52, for a total transaction of $705,200.00. Following the transaction, the director now directly owns 148,218 shares of the company’s stock, valued at approximately $10,452,333.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Jean-Frederic Viret sold 3,159 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $20.44, for a total value of $64,569.96. In the last ninety days, insiders have sold 75,309 shares of company stock valued at $3,381,670. Insiders own 26.30% of the company’s stock.
A number of institutional investors have recently made changes to their positions in MDC. BlackRock Inc. lifted its holdings in shares of M.D.C. by 6.5% in the 2nd quarter. BlackRock Inc. now owns 8,894,057 shares of the construction company’s stock worth $291,547,000 after purchasing an additional 539,112 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in M.D.C. by 305.0% during the second quarter. JPMorgan Chase & Co. now owns 312,176 shares of the construction company’s stock worth $10,056,000 after buying an additional 464,459 shares during the last quarter. Nuveen Asset Management LLC bought a new position in shares of M.D.C. in the second quarter valued at $9,242,000. Bank of New York Mellon Corp lifted its stake in shares of M.D.C. by 11.8% in the second quarter. Bank of New York Mellon Corp now owns 1,686,489 shares of the construction company’s stock valued at $55,283,000 after buying an additional 178,230 shares in the last quarter. Finally, Intrinsic Edge Capital Management LLC bought a new position in shares of M.D.C. in the second quarter valued at $5,069,000. 76.21% of the stock is owned by hedge funds and other institutional investors.
M.D.C. Company Profile
M.DC Holdings, Inc, through its subsidiaries, engages in the homebuilding and financial service businesses. Its homebuilding operations include purchasing finished lots or developing lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the Richmond American Homes name.
Further Reading: Why are gap-down stocks important?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for M.D.C. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for M.D.C. and related companies with MarketBeat.com's FREE daily email newsletter.